Workshop INTA on ACTA : Différence entre versions
(→Programme) |
(→Programme) |
||
Ligne 27 : | Ligne 27 : | ||
*16.15: '''Presentation of the European Parliament’s External Study entitled “The Anti-Counterfeiting Trade Agreement”''' (Policy Department, 2011)<br/> | *16.15: '''Presentation of the European Parliament’s External Study entitled “The Anti-Counterfeiting Trade Agreement”''' (Policy Department, 2011)<br/> | ||
Speakers: Prof. [http://unimaas.academia.edu/ProfAnselmKampermanSandersPhDLond Anselm Kamperman SANDERS] (Maastricht University) Prof. [http://www.maastrichtuniversity.nl/web/Faculteiten/FdR/Thema/OverDeFaculteit/Medewerkers/MedewerkersAbc/ShabalalaD..htm Dalindyebo SHABALALA] (Maastricht University) | Speakers: Prof. [http://unimaas.academia.edu/ProfAnselmKampermanSandersPhDLond Anselm Kamperman SANDERS] (Maastricht University) Prof. [http://www.maastrichtuniversity.nl/web/Faculteiten/FdR/Thema/OverDeFaculteit/Medewerkers/MedewerkersAbc/ShabalalaD..htm Dalindyebo SHABALALA] (Maastricht University) | ||
− | |||
<br/> | <br/> | ||
The presentation will be followed by comments from the European Commission represented by Mr [http://ec.europa.eu/staffdir/plsql/gsys_fonct.properties?pLang=EN&pSernum=604143 Pedro VELASCO MARTINS] | The presentation will be followed by comments from the European Commission represented by Mr [http://ec.europa.eu/staffdir/plsql/gsys_fonct.properties?pLang=EN&pSernum=604143 Pedro VELASCO MARTINS] | ||
Ligne 35 : | Ligne 34 : | ||
Speakers: Dr [http://www.altius.com/en/lawyers/partners/olivier-vrins/ Olivier VRINS] (ALTIUS Lawyers), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE) | Speakers: Dr [http://www.altius.com/en/lawyers/partners/olivier-vrins/ Olivier VRINS] (ALTIUS Lawyers), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE) | ||
<br/> | <br/> | ||
− | |||
**'''''Is ACTA likely to restrict access to medicines in developing countries? Is ACTA a potential danger for trade in generic drugs?'''''<br/> | **'''''Is ACTA likely to restrict access to medicines in developing countries? Is ACTA a potential danger for trade in generic drugs?'''''<br/> | ||
Speakers: Dr [http://lecturer.haifa.ac.il/showen/865 Meir PUGATCH] (University of Haifa), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE) | Speakers: Dr [http://lecturer.haifa.ac.il/showen/865 Meir PUGATCH] (University of Haifa), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE) |
Version du 14 février 2012 à 18:40
This page give all the information on this meeting.
To be informed about the next steps to urge Members of the European Parliament to reject ACTA, send a blank email to NOtoACTA-subscribe@laquadrature.net to subscribe to our list.
To discuss ACTA, subscribe to our discussion list by sending a blank email to acta-subscribe@laquadrature.net. We won't use your email for anything else.
Practical information
Location
European Parliament
Brussels
Paul-Henri Spaak Building
Room P3C050
Time
Thursday, 1 March 2012
From 15.00 to 18.30
Programme
- 15:00 : Welcome and introduction to the workshop by INTA Chairman Prof. Vital MOREIRA
- 15:15: A comprehensive assessment of the “Anti-Counterfeiting Trade Agreement” (ACTA) and the EU IPR protection and enforcement-related trade policies.
Speakers: Mr Karel DE GUCHT (EU Commissioner for Trade), Dr Michael GEIST (University of Ottawa), Prof. Christophe GEIGER (University of Strasbourg)
- 16.15: Presentation of the European Parliament’s External Study entitled “The Anti-Counterfeiting Trade Agreement” (Policy Department, 2011)
Speakers: Prof. Anselm Kamperman SANDERS (Maastricht University) Prof. Dalindyebo SHABALALA (Maastricht University)
The presentation will be followed by comments from the European Commission represented by Mr Pedro VELASCO MARTINS
- 17.15: Specific aspects of ACTA
- The EU acquis and ACTA: Are civil liberties under threat? - What will be the likely impact of ACTA on EU Member States’ national legislation on IPR enforcement?
- The EU acquis and ACTA: Are civil liberties under threat? - What will be the likely impact of ACTA on EU Member States’ national legislation on IPR enforcement?
Speakers: Dr Olivier VRINS (ALTIUS Lawyers), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE)
- Is ACTA likely to restrict access to medicines in developing countries? Is ACTA a potential danger for trade in generic drugs?
- Is ACTA likely to restrict access to medicines in developing countries? Is ACTA a potential danger for trade in generic drugs?
Speakers: Dr Meir PUGATCH (University of Haifa), Mr Rupert SCHLEGELMILCH (Director, European Commission, DG Trade) or Mr Anders JESSEN (Head of Unit, European Commission DG TRADE)
- 18.15 Concluding remarks by INTA rapporteur
- 18.25 Closure of the workshop by INTA Chairman Prof. Vital MOREIRA